Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot safety study of neoadjuvant radiotherapy in glioblastoma
2022-001453-23Phase 2Active
- Sponsor
- Asate Therapeutics
- Start
- Jun 2022
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of temozolomide in glioblastoma (GBM), sponsored by Asate Therapeutics. Primary endpoint: Safety of neoadjuvant radiotherapy. Started Jun 2022; status: active.
02
Drugs
temozolomide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2022-001453-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001453-23.